Alexander Kokkinos Carel Le Roux To view or add a comment, sign in Tirzepatide: Redefining Outcomes in Diabetes & Obesity Care Clinical trials show tirzepatide, a dual GIP/GLP-1 receptor agonist, is delivering results beyond expectations: Up to 20.9% mean weight loss at 72 weeks (SURMOUNT-1, NEJM) 94% risk reduction in progression from prediabetes to type 2 diabetes over 3 years Superior HbA1c reduction and weight control vs leading GLP-1 therapies (SURPASS program) With manageable side effects and durable outcomes, tirzepatide is reshaping how we approach metabolic disease
Features High Specificity Precisely cleaves at the Asp-Asp-Asp-Asp-Lys recognition site
Gather your supplies First, make sure you have access to soap and water so you can wash your hands
Viagra was a drug to treat high blood pressure
While the Medicare GLP-1 Bridge Program has expanded access to certain obesity medications for eligible beneficiaries, not everyone with Medicare will qualify
The Chartered Trading Standards Institute (CTSI) has issued a warning following a Channel 4 News probe that uncovered a rapid rise in the use of unregulated intravenous glutathione drips being marketed for skin lightening, whitening, and brightening across the UK
